Lakewood-Amedex Reports Positive AMR Data for Nu-3
Lakewood-Amedex Biotherapeutics announced positive antimicrobial resistance, or AMR, data for its lead compound, Nu-3, which is being developed as a topically delivered treatment for infected diabetic foot ulcers. Nu-3 is one of a new class of antimicrobial compounds discovered by Lakewood-Amedex Biotherapeutics called the Bisphosphocin class, which are also being explored in pre-clinical studies as potential treatments for complicated urinary tract infection and pulmonary infections. The Bisphosphocin class of compounds have been shown to rapidly kill bacteria, typically in under one minute of exposure. This mechanism of action offers the potential to reduce the threat posed by antibiotic-resistant bacterial strains. In laboratory studies, Nu-3 showed slightly increased Minimum Inhibitory Concentration at the end of the experiment for E. coli and were unchanged for MRSA. In contrast, the MIC for the ciprofloxacin control had increased over 2,000-fold for E. coli and over 600-fold for MRSA. In addition, Nu-3 maintained its original MIC when assessed against the bacteria that had developed resistance to Ciprofloxacin, which implies that cross-resistance did not occur.
